Therapeutic antibodies and infectious diseases: Tours, France, November 20-22, 2012

mAbs

Volumn 5, Issue 5, 2013, Pages 626-632

  Desoubeaux, Guillaume ^a,b   Daguet, Arnaud ^a,c   Watier, Hervé ^a,b,c  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c CNRS   (France)

Author keywords

Antibodies; Immunotherapy; Infectious diseases; Monoclonal

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; BACTERIAL TOXIN; HUMAN IMMUNOGLOBULIN; HUMAN IMMUNOGLOBULIN G1K 35PA83; MONOCLONAL ANTIBODY; NATALIZUMAB; NEUTRALIZING ANTIBODY; PANOBACUMAB; POLYCLONAL ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTHRAX; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ANTIVIRAL ACTIVITY; BIOTECHNOLOGY; CONFERENCE PAPER; FOOD AND DRUG ADMINISTRATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION; LOW DRUG DOSE; MULTIPLE SCLEROSIS; PSEUDOMONAS INFECTION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME;

ANTIBODIES; IMMUNOTHERAPY; INFECTIOUS DISEASES; MONOCLONAL;

ANTI-BACTERIAL AGENTS; ANTIBODIES; ANTIVIRAL AGENTS; COMMUNICABLE DISEASES; HUMANS;

EID: 84883873116     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.25300     Document Type: Conference Paper

References (53)

1. Therapeutic Antibodies and Infectious Diseases [Internet]. Tours, France: Therapeutic Antibodies and Infectious Diseases: 2010 [cited 2013 June 3]. Available at: http://taid.fr/?lang=en.
2. Laboratoire d'excellence MAbImprove | Optimisation du développement des anticorps monoclonaux thérapeutiques [Internet]. Tours, France: LabEx MABImprove: 2013 [cited 2013 March 27]. Available at: http://mabimprove.univ-tours.fr/?lang=en.
3. Infectiologie région Centre [Internet]. Tours, France: Le cluster de recherche en infectiologie de la région Centre: 16 May 2013 [cited 2013 March 27]. Available at: http://www.infectiologie-regioncentre.fr/ Presentation/Le-cluster-de-recherche-en-infectiologiede-la-region-Centre.
4. Laffly E, Danjou L, Condemine F, Vidal D, Drouet E, Lefranc MP, et al. Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob Agents Chemother 2005; 49:3414-20; PMID:16048955; http://dx.doi.org/10.1128/AAC.49.8.3414-3420.2005
5. Laffly E, Pelat T, Cédrone F, Blésa S, Bedouelle H, Thullier P. Improvement of an antibody neutralizing the anthrax toxin by simultaneous mutagenesis of its six hypervariable loops. J Mol Biol 2008; 378:1094-103; PMID:18423488; http://dx.doi.org/10.1016/j. jmb.2008.03.045
6. Janssens R, Dekker S, Hendriks RW, Panayotou G, van Remoortere A, San JK, et al. Generation of heavychain-only antibodies in mice. Proc Natl Acad Sci U S A 2006; 103:15130-5; PMID:17015837; http://dx.doi.org/10.1073/pnas.0601108103
7. Gauduchon V, Werner S, Prévost G, Monteil H, Colin DA. Flow cytometric determination of Panton-Valentine leucocidin S component binding. Infect Immun 2001; 69:2390-5; PMID:11254598; http://dx.doi.org/10.1128/IAI.69.4. 2390-2395.2001
8. Kohler PL, Greenwood SD, Nookala S, Kotb M, Kranz DM, Schlievert PM. Staphylococcus aureus isolates encode variant staphylococcal enterotoxin B proteins that are diverse in superantigenicity and lethality. PLoS One 2012; 7:e41157; PMID:22815951; http://dx.doi. org/10.1371/journal.pone.0041157
9. Bossart KN, Zhu Z, Middleton D, Klippel J, Crameri G, Bingham J, et al. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog 2009; 5:e1000642; PMID:19888339; http://dx.doi. org/10.1371/journal.ppat.1000642
10. Bossart KN, Geisbert TW, Feldmann H, Zhu Z, Feldmann F, Geisbert JB, et al. A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med 2011; 3:ra103; PMID:22013123; http://dx.doi.org/10.1126/scitranslmed.3002901
11. Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A 2012; 109:5034-9; PMID:22411795; http://dx.doi.org/10.1073/pnas.1200409109
12. Avril A, Froude JW, Mathieu J, Pelat T, Thullier P. Isolation of antibodies from non-human primates for clinical use. Curr Drug Discov Technol 2013; PMID:23410051
13. Horn MP, Zuercher AW, Imboden MA, Rudolf MP, Lazar H, Wu H, et al. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrob Agents Chemother 2010; 54:2338-44; PMID:20308370; http://dx.doi.org/10.1128/AAC.01142-09
14. Lu Q, Rouby JJ, Laterre PF, Eggimann P, Dugard A, Giamarellos-Bourboulis EJ, et al. Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. J Antimicrob Chemother 2011; 66:1110-6; PMID:21398296; http://dx.doi.org/10.1093/jac/dkr046
15. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113:3716-25; PMID:19018092; http://dx.doi.org/10.1182/blood-2008-09-179754
16. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012; 119:5640-9; PMID:22535666; http://dx.doi. org/10.1182/blood-2012-01-380121
17. Jönsson F, Mancardi DA, Zhao W, Kita Y, Iannascoli B, Khun H, et al. Human FcγRIIA induces anaphylactic and allergic reactions. Blood 2012; 119:2533-44; PMID:22138510; http://dx.doi.org/10.1182/blood-2011-07-367334
18. Mancardi DA, Albanesi M, Jönsson F, Iannascoli B, Van Rooijen N, Kang X, et al. The high-affinity human IgG receptor FcγRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy. Blood 2013; 121:1563-73; PMID:23293080; http://dx.doi.org/10.1182/blood-2012-07-442541
19. Beerli RR, Bauer M, Schmitz N, Buser RB, Gwerder M, Muntwiler S, et al. Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein. Virol J 2009; 6:224; PMID:20025741; http://dx.doi.org/10.1186/1743-422X-6-224
20. Beerli RR, Bauer M, Buser RB, Gwerder M, Muntwiler S, Maurer P, et al. Isolation of human monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci U S A 2008; 105:14336-41; PMID:18812621; http://dx.doi.org/10.1073/ pnas.0805942105
21. Schmitz N, Beerli RR, Bauer M, Jegerlehner A, Dietmeier K, Maudrich M, et al. Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur J Immunol 2012; 42:863-9; PMID:22531913; http://dx.doi.org/10.1002/eji.201041225
22. Michaud HA, Gomard T, Gros L, Thiolon K, Nasser R, Jacquet C, et al. A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. PLoS Pathog 2010; 6:e1000948; PMID:20548955; http://dx.doi.org/10.1371/journal.ppat.1000948
23. Nasser R, Pelegrin M, Michaud HA, Plays M, Piechaczyk M, Gros L. Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody. J Virol 2010; 84:10169-81; PMID:20610721; http://dx.doi. org/10.1128/JVI.00568-10
24. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al.; Protocol G Principal Investigators. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326:285-9; PMID:19729618; http://dx.doi.org/10.1126/science.1178746
25. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, et al.; Protocol G Principal Investigators. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477:466-70; PMID:21849977; http://dx.doi. org/10.1038/nature10373
26. Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, Weisgrau KL, et al. Highly potent HIVspecific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A 2012; 109:18921-5; PMID:23100539; http://dx.doi.org/10.1073/pnas. 1214785109
27. Poignard P, Sabbe R, Picchio GR, Wang M, Gulizia RJ, Katinger H, et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 1999; 10:431-8; PMID:10229186; http://dx.doi.org/ 10.1016/S1074-7613(00)80043-6
28. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012; 492:118-22; PMID:23103874; http://dx.doi.org/10. 1038/nature11604
29. Jacobo-Molina A, Ding J, Nanni RG, Clark AD Jr., Lu X, Tantillo C, et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A 1993; 90:6320-4; PMID:7687065; http://dx.doi. org/10.1073/pnas.90.13.6320
30. Both L, Banyard AC, van Dolleweerd C, Horton DL, Ma JKC, Fooks AR. Passive immunity in the prevention of rabies. Lancet Infect Dis 2012; 12:397-407; PMID:22541629; http://dx.doi.org/10.1016/S1473-3099(11)70340-1
31. Bakker AB, Python C, Kissling CJ, Pandya P, Marissen WE, Brink MF, et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008; 26:5922-7; PMID:18804136; http://dx.doi. org/10.1016/j.vaccine.2008.08.050
32. Tarr AW, Lafaye P, Meredith L, Damier-Piolle L, Urbanowicz RA, Meola A, et al. An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. Hepatology 2013; PMID:18000990; http://dx.doi.org/10.1002/hep. 26430
33. Zahid MN, Turek M, Xiao F, Thi VL, Guérin M, Fofana I, et al. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology 2013; 57:492-504; PMID:23081796; http://dx.doi. org/10.1002/hep.26097
34. Krieger SE, Zeisel MB, Davis C, Thumann C, Harris HJ, Schnober EK, et al. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology 2010; 51:1144-57; PMID:20069648; http://dx.doi.org/10.1002/hep.23445
35. Fofana I, Krieger SE, Grunert F, Glauben S, Xiao F, Fafi-Kremer S, et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 2010; 139:953-64, e1-4; PMID:20685314; http://dx.doi. org/10.1053/j.gastro.2010.05.073
36. Frandsen TP, Naested H, Rasmussen SK, Hauptig P, Wiberg FC, Rasmussen LK, et al. Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use. Biotechnol Bioeng 2011; 108:2171-81; PMID:21495017; http://dx.doi.org/10.1002/bit.23166
37. King LA, Nogareda F, Weill FX, Mariani-Kurkdjian P, Loukiadis E, Gault G, et al. Outbreak of Shiga toxin-producing Escherichia coli O104:H4 associated with organic fenugreek sprouts, France, June 2011. Clin Infect Dis 2012; 54:1588-94; PMID:22460976; http://dx.doi.org/10.1093/cid/cis255
38. Skurnik D, Davis MR Jr., Benedetti D, Moravec KL, Cywes-Bentley C, Roux D, et al. Targeting panresistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection. J Infect Dis 2012; 205:1709-18; PMID:22448004; http://dx.doi.org/10.1093/infdis/jis254
39. Baer M, Sawa T, Flynn P, Luehrsen K, Martinez D, Wiener-Kronish JP, et al. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect Immun 2009; 77:1083-90; PMID:19103766; http://dx.doi.org/10.1128/IAI.00815-08
40. François B, Luyt CE, Dugard A, Wolff M, Diehl JL, Jaber S, et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med 2012; 40:2320-6; PMID:22622405; http://dx.doi.org/10.1097/CCM.0b013e31825334f6
41. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347:589-600; PMID:12192020; http://dx.doi.org/10.1056/NEJMra020528
42. Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, et al.; EHEC-HUS consortium. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012; 345:e4565; PMID:22815429; http://dx.doi. org/10.1136/bmj.e4565
43. Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008; 67:283-7; PMID:17644544; http://dx.doi.org/10.1136/ ard.2006.065565
44. Visentini M, Ludovisi S, Petrarca A, Pulvirenti F, Zaramella M, Monti M, et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev 2011; 10:714-9; PMID:21570494; http://dx.doi.org/10.1016/j.autrev. 2011.04.033
45. Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, Vizzutti F, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010; 116:335-42; PMID:20308604; http://dx.doi. org/10.1182/blood-2009-11-253948
46. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al.; B S R B R Control Centre Consortium; BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69:522-8; PMID:19854715; http://dx.doi.org/10.1136/ ard.2009.118935
47. Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, et al.; RATIO group. Drugspecific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011; 70:616-23; PMID:21177290; http://dx.doi.org/10.1136/ard.2010.137422
48. Van den Brande JMH, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124:1774-85; PMID:12806611; http://dx.doi.org/10.1016/S0016-5085(03)00382-2
49. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353:375-81; PMID:15947078; http://dx.doi. org/10.1056/NEJMoa051847
50. Vermersch P, Kappos L, Gold R, Foley JF, Olsson T, Cadavid D, et al. Clinical outcomes of natalizumabassociated progressive multifocal leukoencephalopathy. Neurology 2011; 76:1697-704; PMID:21576685; http://dx.doi.org/10.1212/WNL.0b013e31821a446b
51. Bozic C, Richman S, Plavina T, Natarajan A, Scanlon JV, Subramanyam M, et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 2011; 70:742-50; PMID:22162056; http://dx.doi. org/10.1002/ana.22606
52. Rothstein DM, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev 2003; 196:85-108; PMID:14617200; http://dx.doi. org/10.1046/j.1600-065X.2003.00088.x
53. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10:535-46; PMID:20415897; http://dx.doi.org/10.1111/j.1600- 6143.2009.03005.x